Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 41, Issue 5, Pages 1260-1269Publisher
WILEY
DOI: 10.1002/hed.25554
Keywords
decoy receptor 3 (DcR3); metastasis-associated protein 1 (MTA1); oral squamous cell carcinoma (OSCC); patient-derived tumor xenograft (PDTX); triptolide
Categories
Funding
- Cardinal Tien Hospital, Taipei, Taiwan, Republic of China [CJH107A-2C01]
- Medical Affairs Bureau, Ministry of National Defense, Taiwan, Republic of China [MAB-106-090]
- Tri-Service General Hospital, Taiwan, Republic of China [TSGH-C105-006-008-S05, TSGH-C1 06-004-006-008-S05, TSGH-C107-008-S06]
- Ministry of Science and Technology, Taiwan, Republic of China [MOST 105-2314-B-016-021-MY3]
Ask authors/readers for more resources
Background Aberrant expression of decoy receptor 3 (DcR3) is considered to be a diagnostic and therapeutic target for human cancers. The aim of this study was to assess DcR3 as a target of the anticancer effects of triptolide (TPL) in preclinical patient-derived tumor xenograft (PDTX) models of oral squamous cell carcinoma (OSCC). Methods The expression of DcR3 was evaluated through immunohistochemistry, and correlations were examined using clinical variables. The effects of TPL on the expression of DcR3 and cell proliferation were investigated in OSCC cell lines and in PDTX models. Results DcR3 overexpression was associated with overall survival and tumor size. TPL significantly decreased tumor growth. Moreover, TPL inhibited the expression of metastasis-associated protein 1 (MTA1), a transcription factor for DcR3 in vivo, in vitro, and in PDTX models. Conclusion TPL appeared to exert anticancer effects by repressing DcR3 and MTA1 in vitro, in vivo, and in PDTX models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
